Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb said it will buy Nvidia’s latest-generation DGX SuperPOD computing system based on Vera Rubin architecture to expand AI use across drug discovery and development. The deal highlights continued capital spending by life sciences firms on AI infrastructure to speed target identification, narrow down drug candidates earlier, and improve clinical trial success rates. Bristol Myers said it is the first life sciences company to purchase this system, but did not disclose financial terms. Executives said the new platform will expand compute capacity significantly, improve energy efficiency, and support larger AI models across small- and large-molecule programs. The announcement reinforces Nvidia’s role as a core beneficiary of enterprise AI spending, while also underscoring pharma’s push to use AI for faster research timelines and potentially more productive pipelines.